Effect of Metadoxine on Chronic Primary Hepatopathies in Canines:  Number of Cases

Objective. To evaluate the effect of Metadoxine on paraclinical, ultrasound, and histopathological findings in canines with primary hepatopathies through a number of cases. Materials and Methods. Seven dogs aged 2 to 14 years with mild to moderate clinical signs of primary hepatopathy, abnormal bil...

Full description

Saved in:
Bibliographic Details
Main Authors: Paula María Bermúdez-Duarte, José Alfredo Rivera-Rojas
Format: Article
Language:English
Published: Universidad de Cordoba 2023-09-01
Series:Revista MVZ Cordoba
Subjects:
Online Access:https://revistamvz.unicordoba.edu.co/article/view/3103
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1823857961557032960
author Paula María Bermúdez-Duarte
José Alfredo Rivera-Rojas
author_facet Paula María Bermúdez-Duarte
José Alfredo Rivera-Rojas
author_sort Paula María Bermúdez-Duarte
collection DOAJ
description Objective. To evaluate the effect of Metadoxine on paraclinical, ultrasound, and histopathological findings in canines with primary hepatopathies through a number of cases. Materials and Methods. Seven dogs aged 2 to 14 years with mild to moderate clinical signs of primary hepatopathy, abnormal bile acids, increased ALT or ALP values three times above the upper range for 4 weeks, underwent ultrasound evaluation and ultrasound-guided Tru-Cut liver biopsy to confirm hepatopathy according to the histological classification of the WSAVA. Prior to the biopsy, they were required to have fibrinogen >100 mg/dL, platelets >100 cells x 103/µL, and prothrombin time <11.5 seconds. Once the histological diagnosis was confirmed, they received metadoxine at 17±11.35 mg/kg every 12 hours for 4 weeks. Clinical, paraclinical, ultrasound, and histopathological follow-up was conducted at the end of this period. Results. A decrease in the occurrence of vomiting and anorexia was observed (p=0.03), a non-significant increase in ALT and ALP (p=0.84; p=0.43), a reduction in bile acids (p=0.4), and no change in ultrasound score (p=0.42) or histopathological diagnosis (p>0.05). Conclusions. Despite significant limitations, this number of cases provides preliminary observation suggesting that metadoxine may improve the clinical condition of dogs with liver disease without altering paraclinical, ultrasound, or histological variables; additional research with a Randomized Clinical Trial design is needed to propose metadoxine indication protocols for canines with hepatopathies in clinical practice.
format Article
id doaj-art-2b1e88705a4245949436d8b98a0a1c56
institution Kabale University
issn 0122-0268
1909-0544
language English
publishDate 2023-09-01
publisher Universidad de Cordoba
record_format Article
series Revista MVZ Cordoba
spelling doaj-art-2b1e88705a4245949436d8b98a0a1c562025-02-11T17:17:21ZengUniversidad de CordobaRevista MVZ Cordoba0122-02681909-05442023-09-0128310.21897/rmvz.3103Effect of Metadoxine on Chronic Primary Hepatopathies in Canines:  Number of CasesPaula María Bermúdez-Duarte0https://orcid.org/0000-0003-2294-3539José Alfredo Rivera-Rojas1Universidad de la Salle, Colombia.Universidad de la Salle, Colombia. Objective. To evaluate the effect of Metadoxine on paraclinical, ultrasound, and histopathological findings in canines with primary hepatopathies through a number of cases. Materials and Methods. Seven dogs aged 2 to 14 years with mild to moderate clinical signs of primary hepatopathy, abnormal bile acids, increased ALT or ALP values three times above the upper range for 4 weeks, underwent ultrasound evaluation and ultrasound-guided Tru-Cut liver biopsy to confirm hepatopathy according to the histological classification of the WSAVA. Prior to the biopsy, they were required to have fibrinogen >100 mg/dL, platelets >100 cells x 103/µL, and prothrombin time <11.5 seconds. Once the histological diagnosis was confirmed, they received metadoxine at 17±11.35 mg/kg every 12 hours for 4 weeks. Clinical, paraclinical, ultrasound, and histopathological follow-up was conducted at the end of this period. Results. A decrease in the occurrence of vomiting and anorexia was observed (p=0.03), a non-significant increase in ALT and ALP (p=0.84; p=0.43), a reduction in bile acids (p=0.4), and no change in ultrasound score (p=0.42) or histopathological diagnosis (p>0.05). Conclusions. Despite significant limitations, this number of cases provides preliminary observation suggesting that metadoxine may improve the clinical condition of dogs with liver disease without altering paraclinical, ultrasound, or histological variables; additional research with a Randomized Clinical Trial design is needed to propose metadoxine indication protocols for canines with hepatopathies in clinical practice. https://revistamvz.unicordoba.edu.co/article/view/3103liver diseasesDogsimage-guided biopsyPyridoxinepyroglutamic acid
spellingShingle Paula María Bermúdez-Duarte
José Alfredo Rivera-Rojas
Effect of Metadoxine on Chronic Primary Hepatopathies in Canines:  Number of Cases
Revista MVZ Cordoba
liver diseases
Dogs
image-guided biopsy
Pyridoxine
pyroglutamic acid
title Effect of Metadoxine on Chronic Primary Hepatopathies in Canines:  Number of Cases
title_full Effect of Metadoxine on Chronic Primary Hepatopathies in Canines:  Number of Cases
title_fullStr Effect of Metadoxine on Chronic Primary Hepatopathies in Canines:  Number of Cases
title_full_unstemmed Effect of Metadoxine on Chronic Primary Hepatopathies in Canines:  Number of Cases
title_short Effect of Metadoxine on Chronic Primary Hepatopathies in Canines:  Number of Cases
title_sort effect of metadoxine on chronic primary hepatopathies in canines number of cases
topic liver diseases
Dogs
image-guided biopsy
Pyridoxine
pyroglutamic acid
url https://revistamvz.unicordoba.edu.co/article/view/3103
work_keys_str_mv AT paulamariabermudezduarte effectofmetadoxineonchronicprimaryhepatopathiesincaninesnumberofcases
AT josealfredoriverarojas effectofmetadoxineonchronicprimaryhepatopathiesincaninesnumberofcases